Disruption to the Advisory Committee on Immunization Practices has left unresolved questions about measles vaccination, seasonal respiratory vaccines and vaccine research, according to a presentation at IDWeek 2026. Professional societies are providing guidance, but their efforts cannot fully replace the committee’s federal role, panelists said during the session “Opportunities in Vaccine Advocacy and Communication: How to Work Together in Today’s World.”
ACIP’s work extends beyond advising clinicians about which vaccines to recommend. When adopted by the Centers for Disease Control and Prevention, its recommendations influence immunization schedules, insurance coverage and the Vaccines for Children program, according to Rochelle Walensky, MD, MPH, a professor of medicine at Harvard Medical School.
She described ACIP as unable to meet under a court order at the time of the session, with no policies moving forward, including policies concerning Vaccines for Children coverage.
“This leaves a lot of vaccine policies completely unaddressed, including recommendations for broadening vaccines— for example, a zero-dose vaccine in the context of our current measles outbreak— updating seasonal respiratory vaccine recommendations; and addressing really critical gaps in vaccine research,” Dr. Walensky said.
She identified research needs involving RSV revaccination for adults older than 75, COVID-19 vaccination for health care personnel and an mRNA influenza vaccine for older adults. Dr. Walensky also stated that seasonal respiratory vaccine recommendations had not undergone CDC discussion since 2024.
A federal process with clinical implications
Founded in 1964, ACIP replaced earlier ad hoc committees as the number of vaccines and complexity of immunization policy increased. Its designation as a federal advisory committee in 1972 formalized requirements for transparency, public meetings and independent expert review, according to Dr. Walensky’s presentation.
Working groups review evidence and develop proposals for the committee’s consideration. ACIP publicly reviews evidence using an evidence-to-recommendation framework, votes and submits recommendations to the CDC director.
The framework addresses benefits and harms alongside public health importance, values, acceptability, resource use, equity and feasibility. Since 1993, ACIP has also had authority to determine which vaccines are covered through Vaccines for Children.
Dr. Walensky traced the transition through the removal and replacement of ACIP members in June 2025, a federal overhaul of the childhood immunization schedule in January 2026 and a March court order blocking schedule and membership changes. She also described a June 2026 charter that narrowed the committee’s vaccine recommendation role and emphasized assessing alternatives for disease prevention.
The March court order stemmed from a lawsuit filed by IDSA and other medical and public health organizations challenging the qualifications and appointment process of newly selected ACIP members, as well as recommendations the plaintiffs argued were inconsistent with scientific evidence.
Against that backdrop, professional societies have published their own recommendations. Jason Goldman, MD, MACP, immediate past president of the American College of Physicians, emphasized both the importance and limits of that response.
“We have to recognize that as good as we are, as good as the professional societies are, we cannot replace a fully staffed, vetted, functioning, appropriately constituted ACIP. We just can’t. We don’t have those resources,” Dr. Goldman said. “I don’t see this as a long-term solution. It is a Band-Aid, but a necessary one to stop the hemorrhaging.”
The Department of Health and Human Services is also accepting nominations for new ACIP members through Dec. 31, 2026. IDSA, which has called for restoring ACIP’s established vaccine recommendation process with qualified, appropriately vetted members, is encouraging eligible experts to apply or nominate colleagues. The society said a broad pool of qualified candidates could support efforts to restore an evidence-based federal vaccine advisory process.
Explaining the basis for recommendations
The disrupted federal process also provided context for questions about how clinicians should assess guidance and explain their recommendations to patients.
Asked how clinicians should interpret updates to CDC webpages, Demetre Daskalakis, MD, MPH, chief medical officer at Callen-Lorde Community Health Center in Brooklyn, New York, advised verification through other sources.
“I tend to say that the best thing to do is to rely on other sources to verify whether or not you should believe what you’re seeing at CDC,” he said.
Dr. Walensky emphasized transparency about the evidence underlying recommendations. She described the Vaccine Integrity Project’s publication of search protocols and information about its evidence reviews so others can examine how conclusions were reached.
For patient conversations, Dr. Goldman advised listening to identify the concern behind a question, explaining the data supporting a recommendation and encouraging scrutiny of information sources. Describing his response to parents encountering conflicting information, he emphasized earning trust while welcoming questions.
“[I tell them], ‘I want you to trust me, but I have to earn that trust. But I want you to question as well. Question me, question the source, don’t just come in and say [you] read this online so it must be true.’”
Dr. Daskalakis reported advisor/consultant relationships with AstraZeneca, Merck, Sanofi Pasteur and ViiV, and honoraria from Gilead. Dr. Goldman reported no financial relationships to disclose. Dr. Walensky disclosed serving as a Bayer Fellow in Health and Biotech at the American Academy in Berlin, and a board position and ownership interest in Immunobrain.